RORgamma modulators and uses thereof

Patent metadata

Field	Value
Publication number	US-11974997-B2
Application number	US-202117494458-A
Country	US
Kind code	B2
Filing date	Oct 5, 2021
Priority date	Jan 27, 2017
Publication date	May 7, 2024
Grant date	May 7, 2024

Abstract

The present invention provides novel compounds that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.

First claim

The invention claimed is:

1. A compound of formula (I)

in which,
R1a is a hydrogen atom, a halogen atom, a nitrile group, a nitro group (NO2), a (C1-C6)alkyl group, a (C1-C6)alkyloxy group, a (C1-C6)alkylthio group, an amino group, a (C1-C6)alkylamino group, a (C1-C6)dialkylamino group, or a heterocyclic group;
R1b is a hydrogen atom, a (C1-C6)alkyloxy group, a (C1-C6)alkyl group, or a heterocyclic group;
R1c is a hydrogen atom, a halogen atom, a (C1-C6)alkyl group, a (C1-C6)alkyloxy group, a (C1-C6)alkylthio group, a heterocyclic group, a cyano group, an amido group, or a hydroxyl group;
R1d and R1e are, independently, a hydrogen atom, a halogen atom, a (C1-C6)alkyloxy group, or a (C1-C6)alkyl group;
wherein at least one of R1a, R1b, R1c, R1d, and R1e is not a hydrogen atom;
R2 is a (C1-C6)alkyl group optionally substituted by a (C1-C6)alkyl group, a (C2-C6)alkenyl group optionally substituted by a (C1-C6)alkyl group, a (C2-C6)alkynyl group optionally substituted by a (C1-C6)alkyl group, a (C3-C14)cycloalkyl group optionally substituted by a (C1-C6)alkyl group, a (C6-C14)aryl group optionally substituted by a (C1-C6)alkyl group, or a heterocyclic group optionally substituted by a (C1-C6)alkyl group;
R′2 is a hydrogen atom, a (C1-C6)alkyl group, a (C2-C6)alkenyl group, a (C2-C6)alkynyl group, a (C3-C14)cycloalkyl group, a (C6-C14)aryl group optionally substituted by a (C1-C6)alkyl group, or a heterocyclic group optionally substituted by a (C1-C6)alkyl group;
or R2 and R′2, together with the carbon atom to which they are attached, form a cycloalkyl group or a heterocycloalkyl group;
L1 is a NR7-CO—CH2, NR7-CO—, NR7-CO—C(CH3)2, CO—NH—CH2, CO—NH, or CO—NH—C(CH3)2 group;
R7 is a hydrogen atom or a (C1-C6)alkyl group;
L2 represents a bond, a (C1-C6)alkyl group, a (C3-C14)cycloalkyl group, or a CR8R′8 group;
with the proviso that when L1 is a NR3-CO— or a CO—NH group, L2 represents a (C1-C6)alkyl group, a (C3-C14)cycloalkyl group, or a CR8R′8 group;
R8 and R′8 are independently a hydrogen atom or a (C1-C6)alkyl group, or R8 and R′8, together with the carbon atom to which they are attached, form a cycloalkyl group;
X1, X2, X3, X4 and X5 are, independently, a CH group, a C-R4 group, a C—X6 group, or a nitrogen atom;
wherein two and only two of X1, X2, X3, X4, and X5 are nitrogen atoms, and said nitrogen atoms are in 1-position and 3-position;
X6 and X7 are independently a CH group or a nitrogen atom;
R3 is a hydrogen atom, a carbonyl(C1-C6)alkyl group, a SO2R′ group, a COOR′ group, an amido group, a (C1-C6)alkylamido group, or a (C1-C6)dialkylamido group;
R′ is a (C1-C6)alkyl group; and
R4 is a hydrogen atom, a (C1-C6)alkyl group, or a halogen atom.

2. The compound according to claim 1 , wherein X2 and X4 are nitrogen atoms.

3. The compound according to claim 1 , wherein:
R1a is a hydrogen atom, a halogen atom, a nitrile group, a nitro group (NO2), a (C1-C6)alkyl group, a (C1-C6)alkyloxy group, a (C1-C6)alkylthio group, an amino group, a (C1-C6)alkylamino group, a (C1-C6)dialkylamino group, a piperidinyl group, a pyrrolidinyl group, or an azepanyl group, wherein said piperidinyl, pyrrolidinyl, or azepanyl group is optionally substituted by at least one (C1-C6)alkyl group;
R1b is a hydrogen atom;
R1c is a (C1-C6)alkyl group;
R2 is a (C1-C6)alkyl group, a (C3-C14)cycloalkyl group, an (C6-C14)aryl group, or a heteroaryl group; and
R′2 is a hydrogen atom.

4. The compound according to claim 1 , wherein X6 is a nitrogen atom and X7 is a CH group.

5. The compound according to claim 1 , wherein L1 is a NR7-CO—CH2, NR7-CO—C(CH3)2, CO—NH—CH2, or CO—NH—C(CH3)2 group and L2 is a bond.

6. The compound according to claim 1 , wherein L1 is a NR7-00- or —CO—NH— group and L2 is a cyclopropyl group of formula (III)

7. The compound according to claim 1 , wherein R1b is a hydrogen atom.

8. The compound according to claim 1 , wherein R1d and R1e each are a hydrogen atom.

9. The compound according to claim 1 , wherein
R1a is a heterocyclic group,
R1c is a (C1-C6)alkyl group,
R2 is a heterocyclic group,
L1 represents a NH—CO—CH2 group,
L2 is a bound,
the cycle

is in para or meta position of the L group,
X6 is a nitrogen atom,
X7 is a CH group, and
R3 represents a hydrogen atom, a carbonyl(C1-C6)alkyl group, a SO2R′ group, or a COOR′ group.

10. The compound according to claim 1 , characterized in that it is selected from the group consisting of:
2[2-(4-methanesulfonylpiperazin-1-yl)pyrimidin-5-yl]-N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}acetamide;
2[2-(4-methanesulfonylpiperidin-1-yl)pyrimidin-5-yl]-N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}acetamide;
2[2-(4-acetylpiperidin-1-yl)pyrimidin-5-yl]-N-[(2,4-dimethylphenyl)(5-methylfuran-2-yl)methyl]acetamide;
methyl 1-{5-[({[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}carbamoyl)methyl]pyrimidin-2-yl}piperidine-4-carboxylate;
2[2-(4-acetylpiperidin-1-yl)pyrimidin-5-yl]-N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}acetamide;
1-{5-[({[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}carbamoyl)methyl]pyrimidin-2-yl}piperidine-4-carboxylic acid;
1-[2-(4-acetylpiperazin-1-yl)pyrimidin-5-yl]-N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}cyclopropane-1-carb oxamide;
2[2-(4-acetylpiperazin-1-yl)pyrimidin-5-yl]-N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}acetamide; and
2-[2-(3-methanesulfonylpiperidin-1-yl)pyrimidin-5-yl]-N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}acetamide.

11. A combination product comprising:
i) a compound of formula (I) as defined in claim 1 , or a pharmaceutically acceptable salt thereof; and
ii) another therapeutically active agent that is a PPAR activator selected from the group consisting of seladelpar, saroglitazar, lanifibranor, pioglitazone, and pharmaceutically acceptable salts thereof.

12. The combination product according to claim 11 , wherein the combination product is a composition comprising component i), component ii), and a pharmaceutically acceptable carrier.

13. The combination product according to claim 11 , wherein the combination product is a kit of parts comprising components i) and ii), for sequential, separate or simultaneous use.

14. The combination product according to claim 11 , wherein components i) and ii) are formulated in an injectable suspension, a gel, an oil, a pill, a tablet, a suppository, a powder, a capsule, an aerosol, an ointment, a cream, a patch, or means of galenic forms for a prolonged and/or slow release.

Assignees

• Genfit

Inventors

• Delhomel Jean-Francois
• Perspicace Enrico
• Majd Zouher
• Parroche Peggy
• Walczak Robert
• Bonnet Pascal
• Fogha Jade

Classifications

• A61K31/192

  having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid  {(cannabinoids A61K31/658)} · CPC title

• A61K31/496 Primary

  Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title

• A61K31/40

  having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil · CPC title

• A61K31/4184

  condensed with carbocyclic rings, e.g. benzimidazoles · CPC title

• A61K31/4439

  containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) · CPC title